About
Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administere
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
ABBV
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- AbbVie Q4 in focus as Humira patent cliff reaches one-year mark
- U.S. govt. opens bids in Medicare drug price negotiations
- AbbVie raised to Outperform at William Blair ahead of earnings
- Big Pharma earnings season in spotlight amid positive sentiment
- PBMs ramp up lobbying efforts amid growing public scrutiny
- Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia
- AbbVie inks licensing pact with Enigma Biomedical for neuro biomarkers
- AbbVie goes ex dividend tomorrow
- AbbVie sees maintaining Botox position in aesthetics: report
- AbbVie announces EU availability of Parkinson's therapy
- AbbVie advancing hidradenitis suppurative drug to Phase 3
- J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up
- Florida wins FDA nod for mass drug imports from Canada (update)
- AbbVie in pact with Umoja to develop CAR-T cell therapies
- 4 stocks to watch on Thursday: AbbVie, APA Corp. and more
- CVS to drop Humira from certain formularies, cover biosimilars instead
- What's in store for biotech M&A and IPOs in 2024?
- Morgan Stanley positive on healthcare services despite election year
- Pharma and biotech deal values spike 35% in 2023: report
- FDA’s new drug approvals for 2023 rise 51% from last year
Earnings History
| Date | EPS / Forecast | Revenue / Forecast | |
|---|---|---|---|
| February 2, 2022 | 3.31 / 3.29 | 14.89B / 14.96B | |
| October 29, 2021 | 3.33 / 3.21 | 14.34B / 14.3B |
Beat! |
| July 30, 2021 | 3.11 / 3.08 | 13.96B / 13.63B |
Beat! |
| April 30, 2021 | 2.95 / 2.81 | 13.01B / 12.77B |
Beat! |
| February 3, 2021 | 2.92 / 2.85 | 13.86B / 13.7B |
Beat! |
| October 30, 2020 | 2.83 / 2.76 | 12.9B / 12.72B |
Beat! |
| July 31, 2020 | 2.34 / 2.2 | 10.43B / 9.94B |
Beat! |
| May 1, 2020 | 2.42 / 2.25 | 8.62B / 8.33B |
Beat! |
| February 7, 2020 | 2.21 / 2.19 | 8.7B / 8.69B |
Beat! |
| January 27, 2020 | - / 2.2 | - / 8.7B | |
| November 1, 2019 | 2.33 / 2.3 | 8.48B / 8.38B |
Beat! |
| July 26, 2019 | 2.26 / 2.21 | 8.26B / 8.1B |
Beat! |
| April 25, 2019 | 2.14 / 2.06 | 7.83B / 7.77B |
Beat! |
| January 25, 2019 | 1.9 / 1.94 | 8.31B / 8.37B | |
| November 2, 2018 | 2.14 / 2.01 | 8.24B / 8.23B |
Beat! |
| July 27, 2018 | 2 / 1.97 | 8.26B / 8.22B |
Beat! |
| April 26, 2018 | 1.87 / 1.79 | 7.93B / 7.6B |
Beat! |
| January 26, 2018 | 1.48 / 1.44 | 7.74B / 7,530M |
Beat! |
| October 27, 2017 | 1.41 / 1.38 | 7.00B / 6,998M | |
| July 28, 2017 | 1.42 / 1.40 | 6.94B / 6,929M |
Beat! |
| April 27, 2017 | 1.28 / 1.39 | 6.54B / - |
Beat! |
| January 27, 2017 | 1.2 / 1.26 | 6.80B / 6.92B |